Literature DB >> 22595628

Dynamics of targeted cancer therapy.

Ivana Bozic1, Benjamin Allen, Martin A Nowak.   

Abstract

Targeted cancer therapies offer renewed hope for an eventual 'cure for cancer'. At present, however, their success is often compromised by the emergence of resistant tumor cells. In many cancers, patients initially respond to single therapy treatment but relapse within months. Mathematical models of somatic evolution can predict and explain patterns in the success or failure of anticancer drugs. These models take into account the rate of cell division and death, the mutation rate, the size of the tumor, and the dynamics of tumor growth including density limitations caused by geometric and metabolic constraints. As more targeted therapies become available, mathematical modeling will provide an essential tool to inform the design of combination therapies that minimize the evolution of resistance.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22595628      PMCID: PMC3372676          DOI: 10.1016/j.molmed.2012.04.006

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  56 in total

1.  Evolution of resistance during clonal expansion.

Authors:  Yoh Iwasa; Martin A Nowak; Franziska Michor
Journal:  Genetics       Date:  2006-04       Impact factor: 4.562

2.  Pre-existence and emergence of drug resistance in HIV-1 infection.

Authors:  S Bonhoeffer; M A Nowak
Journal:  Proc Biol Sci       Date:  1997-05-22       Impact factor: 5.349

3.  Virus dynamics and drug therapy.

Authors:  S Bonhoeffer; R M May; G M Shaw; M A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

4.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

5.  Rationale for the use of alternating non-cross-resistant chemotherapy.

Authors:  J H Goldie; A J Coldman; G A Gudauskas
Journal:  Cancer Treat Rep       Date:  1982-03

6.  Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.

Authors:  Cristina R Antonescu; Peter Besmer; Tianhua Guo; Knarik Arkun; Glory Hom; Beata Koryotowski; Margaret A Leversha; Philip D Jeffrey; Diann Desantis; Samuel Singer; Murray F Brennan; Robert G Maki; Ronald P DeMatteo
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

7.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Authors:  Alexa B Turke; Kreshnik Zejnullahu; Yi-Long Wu; Youngchul Song; Dora Dias-Santagata; Eugene Lifshits; Luca Toschi; Andrew Rogers; Tony Mok; Lecia Sequist; Neal I Lindeman; Carly Murphy; Sara Akhavanfard; Beow Y Yeap; Yun Xiao; Marzia Capelletti; A John Iafrate; Charles Lee; James G Christensen; Jeffrey A Engelman; Pasi A Jänne
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

8.  Application of theoretical models to chemotherapy protocol design.

Authors:  J H Goldie; A J Coldman
Journal:  Cancer Treat Rep       Date:  1986-01

Review 9.  Targeted cancer therapy.

Authors:  Charles Sawyers
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

10.  A two-stage theory of carcinogenesis in relation to the age distribution of human cancer.

Authors:  P ARMITAGE; R DOLL
Journal:  Br J Cancer       Date:  1957-06       Impact factor: 7.640

View more
  37 in total

Review 1.  Evolutionary scalpels for dissecting tumor ecosystems.

Authors:  Daniel I S Rosenbloom; Pablo G Camara; Tim Chu; Raul Rabadan
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2016-12-05       Impact factor: 10.680

2.  Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model.

Authors:  Federico Perche; Niravkumar R Patel; Vladimir P Torchilin
Journal:  J Control Release       Date:  2012-09-10       Impact factor: 9.776

3.  Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies.

Authors:  Aaron N Hata; Harald Paganetti; Clemens Grassberger; David McClatchy; Changran Geng; Sophia C Kamran; Florian Fintelmann; Yosef E Maruvka; Zofia Piotrowska; Henning Willers; Lecia V Sequist
Journal:  Cancer Res       Date:  2019-05-21       Impact factor: 12.701

4.  The value of monitoring to control evolving populations.

Authors:  Andrej Fischer; Ignacio Vázquez-García; Ville Mustonen
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-13       Impact factor: 11.205

5.  Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers.

Authors:  Ivana Bozic; Martin A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-27       Impact factor: 11.205

Review 6.  Non-coding RNA networks in cancer.

Authors:  Eleni Anastasiadou; Leni S Jacob; Frank J Slack
Journal:  Nat Rev Cancer       Date:  2017-11-24       Impact factor: 60.716

Review 7.  Modeling Tumor Clonal Evolution for Drug Combinations Design.

Authors:  Boyang Zhao; Michael T Hemann; Douglas A Lauffenburger
Journal:  Trends Cancer       Date:  2016-03

8.  The impact of cell density and mutations in a model of multidrug resistance in solid tumors.

Authors:  James Greene; Orit Lavi; Michael M Gottesman; Doron Levy
Journal:  Bull Math Biol       Date:  2014-02-20       Impact factor: 1.758

Review 9.  Hsp90, an unlikely ally in the war on cancer.

Authors:  Jared J Barrott; Timothy A J Haystead
Journal:  FEBS J       Date:  2013-02-24       Impact factor: 5.542

10.  A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity.

Authors:  Bartlomiej Waclaw; Ivana Bozic; Meredith E Pittman; Ralph H Hruban; Bert Vogelstein; Martin A Nowak
Journal:  Nature       Date:  2015-08-26       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.